Oncology-focused drug development company Curis has obtained the conditional approval for Erivedge (vismodegib) to treat adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery ...
Oncology-focused company Curis has announced the approval of Erivedge (vismodegib) in Australia for the treatment of metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma in adult patients who are not suitable for ...
Tags: Curis, Erivedge Anti-Cancer Drug
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has announced positive opinion for conditional approval of Curis' Erivedge in European Union. Erivedge (vismodegib) is used to treat adults with ...
Curis, a drug development company, has reported a net loss of $3.38m, or $0.04 per share, for the third quarter ended 30 September 2012 compared to a net loss of $4.21m, or $0.05 per share, for the third quarter ended 30 September 2011. ...
Tags: Net Loss, proprietary and licensed programs, clinical trial